Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine

Histone deacetylase inhibitors (HDACis) have emerged as a new class of anticancer agents, targeting the biological process including cell cycle and apoptosis. We investigated and explained the anticancer effects of an HDAC6 inhibitor, ricolinostat alone and in combination with bendamustine in lympho...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosenza, Maria, Civallero, Monica, Marcheselli, Luigi, Sacchi, Stefano, Pozzi, Samantha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401712/
https://www.ncbi.nlm.nih.gov/pubmed/28315173
http://dx.doi.org/10.1007/s10495-017-1364-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401712/
https://www.ncbi.nlm.nih.gov/pubmed/28315173
http://dx.doi.org/10.1007/s10495-017-1364-4

Ejemplares similares